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Background
Inhaled corticosteroids (ICS) are recommended for children with 
moderate or severe persistent asthma. The aims of this paper 
were to determine changes in childhood asthma management 
rates between 2004–14, and to examine current medication use 
and level of control in children attending general practice.
Method
National BEACH data were used to investigate childhood 
(<15 years) asthma management rate. Prevalence, medication 
use and asthma control (Global Initiative for Asthma guidelines) 
were recorded for a subset of children.
Results
The management rate did not change over time. Prevalence 
was 13.7%. ICS were taken by 42.8% of children. Asthma 
was well controlled for 51.8%, partly controlled for 30.4% and 
uncontrolled for 17.9% of children. This study highlights the 
need to monitor appropriate medication use, particularly ICS/
long-acting β-agonist use, for asthma control in children.
sthma is among the most commonly managed chronic 
problems in general practice.1 About 2.3 million 
Australians (10.2%) had asthma in 2011–12, a significantly 
lower prevalence than in 2001 (11.6%).2 About 11% of boys 
and 6% of girls aged 0–14 years have diagnosed asthma.3 
Inhaled corticosteroids (ICS) are increasingly used for first-line 
management in adults and children and the 2014 Australian Asthma 
Handbook advocates commencement at a lower threshold of 
symptoms than was recommended previously for adults and 
adolescents.4 For children, ICS are recommended as a first choice 
prevention treatment only in those with moderate or severe 
persistent asthma, and at the lowest effective dose.4 Regular 
review is advised in children to avoid the risk of adverse effects 
associated with long-term ICS use.5 
Our aims were to determine changes in general practice asthma 
management rates among children over the past decade, and to 
examine current medication use and level of control in a recent 
sample of children with asthma aged <15 years.
Method
This is a secondary analysis of data from the Bettering the 
Evaluation And Care of Health (BEACH) program and of a program 
sub-study. BEACH methods are described in detail elsewhere.6 
Changes in rates of asthma management in children from 
2005–2014 are reported. We calculated proportions and robust 
95% confidence intervals using survey procedures in SAS (version 
9.3)7 that adjust for the study’s cluster design. 
Prevalence data were gathered during July and August 2014 
from a Supplementary Analysis of Nominated Data (SAND)  
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sub-study.8 GPs recorded whether the patient had diagnosed 
asthma;8 current asthma medications; and asthma control assessed 
using the Global Initiative for Asthma (GINA) tool.9 Specifically, 
patients were asked if they had experienced asthma symptoms in 
the last 4 weeks, used reliever medication more than twice a week, 
or had been limited in their activity9 (carers were asked to respond 
on behalf of children). Although patients of all ages were sampled, 
these results are limited to children aged <15 years. 
Results 
Management of asthma: From 2005–2014, there were 61,229 
BEACH encounters with children aged <5 years and 50,968 
encounters with children aged 5–14 years. The rate of asthma 
management did not change significantly over the time period for 
patients in either age group, averaging 3.4 per 100 encounters 
for those <5 years and 6.3 per 100 encounters for those aged 
5–14 years across the decade (Figure 1).
Prevalence: Completed asthma SAND questions were returned 
by 97 of 125 general practitioners (GPs; 77.6%). Among these, GPs 
surveyed 409 patients aged <15 years, the age and sex distribution 
of whom did not differ significantly from those of children who 
attended all BEACH encounters in 2013–14. Of the 409 patients, 56 
(13.7%, 95% CI: 10.3–17.1) had diagnosed asthma (17.5% of boys 
and 9.2% of girls). Two-thirds of the patients with asthma were 
boys. Of children aged 1–4 years, 8.7% had diagnosed asthma 
as did 23.8% of those aged 5–14 years. Because the sample size 
was small (n = 56), the group was analysed as a whole rather than 
separating them into <5 years and 5 to <15 years age groups.
Medication use and asthma control: Forty-five patients were 
taking medication for their asthma; salbutamol accounted for 
almost two-thirds (63.8%) of the 69 medications recorded.  
Twenty-four children taking medication for asthma (42.8%) were 
taking an ICS or ICS/LABA (combination). 
Using the GINA guidelines, half of the patients with asthma 
had experienced symptoms in the previous 4 weeks. Twenty-nine 
patients (51.8%, 95% CI:37.9–65.7) had no symptoms (considered 
well controlled), 17 patients (30.4%; 95% CI: 18.9–41.8) had one or 
two (partly controlled) and 10 patients (17.9%, 95% CI: 6.4–29.3) had 
experienced three or four symptoms (uncontrolled). Among patients 
on ICS or ICS/long-acting β-agonists (LABA), eight were well 
controlled, nine were partly controlled and seven were uncontrolled.
All nine patients taking no medication were categorised as 
having well-controlled asthma. There were 21 patients for whom 
ashort-acting β-agonist (SABA) was reported to be the only asthma 
medication taken. Of these, 12 were well controlled, seven were 
partly controlled and two were uncontrolled. ICS/LABA were taken 
in combination by 10 patients: three well controlled, four partly 
controlled and three uncontrolled.
The reported daily doses of ICS aligned with those 
recommended,10 with the exception of six patients on twice the 
recommended dose. Two of these had uncontrolled asthma and the 
other four were well controlled.
Discussion
These results show that the rate of asthma management in 
general practice for children <15 years did not change significantly 
over the decade. The prevalence was higher in boys than girls, 
supporting results of the Australian Health Survey 2011–12, which 
also found asthma in children <15 years to be significantly more 
common in males than females.2
Figure 1. Asthma management rate at GP–patient encounters
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A previous study found good correlation between GPs’ 
perception of asthma control and patients’ individual ACQ5 
scores.11 There seems a similar fit for the patients in this study, 
given they were, overall, appropriately medicated for their asthma 
control level as determined by the GINA guidelines.9 The patients 
who took no medication were all in the well-controlled group, and 
no partly controlled or uncontrolled patients were unmedicated. 
Patients taking only SABAs were mostly well controlled, 
although there may be patients who could benefit from ICS, given 
there were nine patients ranked as partly controlled or uncontrolled 
who were taking only SABAs. There are differences in GP attitudes 
and familiarity with current guidelines relating to childhood asthma 
management;12 however, while some GPs may be less familiar 
with guidelines, others may be cautiously concerned about 
adverse events associated with ICS use, particularly in the long 
term.5 Others may consider the benefits of ICS use outweigh 
the risk for individual patients with uncontrolled asthma, but risk 
can be minimised by using the lowest effective dose.5 Constant 
review is important for all users, particularly in the case of patients 
on higher than recommended doses, such as the six patients 
reported in this study. Also of concern are the 10 patients on ICS/
LABA combination therapy, given the potential for adverse effects 
associated with LABAs in children.13 These children may have been 
prescribed according to asthma control level initially, but only three 
of these patients were ranked as uncontrolled currently.
Some limitations should be considered. The GINA guidelines are 
designed for patients >5 years of age and were used for this sub-
study because, although only children’s results are reported here, 
it surveyed all patients. However, we believe they are a reasonable 
guide for asthma control in these young patients. Encounters with 
children contribute a small proportion of total GP workload (about 
one in eight),1 reflected in the small sample size. Some results 
(denominator n < 30) should be interpreted with caution. Further 
research involving larger patient numbers would provide more 
reliability. 
One in eight children aged <15 years have diagnosed asthma 
and the GP management rate has not changed over the past 
decade. While most children are appropriately medicated according 
to their asthma status, this study highlights the need to continually 
monitor appropriate medication use for asthma control in children 
so that ICS, and particularly LABA, are not prescribed for children 
who do not need them.
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